TY - JOUR
T1 - COVID-19 vaccination challenges
T2 - a mini-review
AU - Mohseni Afshar, Zeinab
AU - Barary, Mohammad
AU - Hosseinzadeh, Rezvan
AU - Karim, Bardia
AU - Ebrahimpour, Soheil
AU - Nazary, Kosar
AU - Sio, Terence T.
AU - Sullman, Mark J.M.
AU - Carson-Chahhoud, Kristin
AU - Moudi, Emaduddin
AU - Babazadeh, Arefeh
N1 - Publisher Copyright:
© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.
PY - 2022
Y1 - 2022
N2 - The emergence of SARS-CoV-2 has led to the infection of many people across the globe, over six million deaths, and has placed an unprecedented burden on public health worldwide. The pandemic has led to the high-speed development and production of vaccines against the COVID-19, as vaccines can end the pandemic. At the beginning of the program, vaccinations were initially targeted only at high-risk groups, such as the elderly, those with comorbidities, or healthcare workers. Although most of the mentioned populations have received the two recommended doses, limited resources have left many authorities with an effective vaccine undersupply. Therefore, policies have been implemented to manage the available doses of the vaccines more efficiently. As there is no universally agreed consensus on this topic, we discuss the different recommendations and guidelines regarding the time interval between the two vaccine doses and explain the different scenarios for applying the two doses.
AB - The emergence of SARS-CoV-2 has led to the infection of many people across the globe, over six million deaths, and has placed an unprecedented burden on public health worldwide. The pandemic has led to the high-speed development and production of vaccines against the COVID-19, as vaccines can end the pandemic. At the beginning of the program, vaccinations were initially targeted only at high-risk groups, such as the elderly, those with comorbidities, or healthcare workers. Although most of the mentioned populations have received the two recommended doses, limited resources have left many authorities with an effective vaccine undersupply. Therefore, policies have been implemented to manage the available doses of the vaccines more efficiently. As there is no universally agreed consensus on this topic, we discuss the different recommendations and guidelines regarding the time interval between the two vaccine doses and explain the different scenarios for applying the two doses.
KW - COVID-19
KW - immunization
KW - SARS-CoV-2
KW - vaccine
KW - vaccine development
UR - http://www.scopus.com/inward/record.url?scp=85132649311&partnerID=8YFLogxK
U2 - 10.1080/21645515.2022.2066425
DO - 10.1080/21645515.2022.2066425
M3 - Review article
C2 - 35512088
AN - SCOPUS:85132649311
SN - 2164-5515
JO - Human Vaccines and Immunotherapeutics
JF - Human Vaccines and Immunotherapeutics
ER -